Related Experiment Video
Updated: May 20, 2025
11:32
Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
Published on: January 3, 2025
582
Catestatin in Cardiovascular Diseases
Joanna Kulpa1, Jarosław Paduch1, Marcin Szczepanik1
1Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland.
International Journal of Molecular Sciences
|March 27, 2025
Summary
Catestatin (CTS) plays a key role in cardiovascular diseases like hypertension, coronary artery disease, and heart failure. This review explores CTS
Area of Science:
- Cardiovascular Science
- Molecular Biology
- Pharmacology
Background:
- Cardiovascular diseases (CVDs) are a major global health burden.
- Complex pathogenesis involves cellular and molecular interactions.
- Catestatin (CTS) emerges as a significant factor in CVD development.
Purpose of the Study:
- To review the role of catestatin (CTS) in cardiovascular disease pathogenesis.
- To discuss CTS's influence on arterial hypertension, coronary artery disease, and heart failure.
- To present CTS's impact on cardiac and vascular function.
Main Methods:
- Literature review of existing research on catestatin (CTS).
- Analysis of studies investigating CTS in cardiovascular contexts.
- Synthesis of findings on CTS's role in heart and vessel physiology and pathology.
Main Results:
- Catestatin (CTS) is implicated in the pathogenesis of major cardiovascular conditions.
- CTS influences key aspects of heart and blood vessel function.
- Emerging evidence highlights CTS's therapeutic potential in CVDs.
Conclusions:
- Catestatin (CTS) is a critical molecule in cardiovascular health and disease.
- Understanding CTS's mechanisms offers potential for novel therapeutic strategies.
- Further research into CTS is warranted for effective CVD treatment.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
354
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
354
01:22Heart Failure Drugs: β-Blockers
299
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
299
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
39
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
39
01:26Heart Failure Drugs: Inotropic Agents
476
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
476
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
123
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
123
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
691
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
691